Funding Opportunity Announcements for Dissemination and Implementation Research in Health, Notice of Reissuance (R01 & R21 Clinical Trials Optional, R03 Clinical Trial Not Allowed)
Posted by: National Cancer Institute (NCI)
Post date: May 10, 2022
Due date: January 8, 2025
Through these PARs, NCI seeks to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g., cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.
For more information, see the postings for R01, R03, and R21.